Truist Securities strengthens its biotech equity research coverage
Truist Securities has announced the appointment of Danielle Brill as managing director to strengthen its biotechnology equity research coverage. Brill, formerly at Raymond James, brings expertise in neurology, hematology, and autoimmune diseases research. She joins the existing biotech and specialty pharma analyst team.
The firm has made several key appointments to expand its equity platform: Rob Muir as managing director and associate director of equity research, a team from Autonomous Research including John McDonald, Brian Foran, and David Smith covering banking sectors, Matt Coad focusing on FinTech, and managing directors Paul Durnan, David McCormick, and Charles de Roziere strengthening sales initiatives.
Truist Securities ha annunciato la nomina di Danielle Brill come direttore generale per rafforzare la sua copertura di ricerca azionaria nel settore delle biotecnologie. Brill, in precedenza presso Raymond James, porta con sé competenze nella ricerca su neurologia, ematologia e malattie autoimmuni. Si unisce al team esistente di analisti nel settore biotech e farmaceutico specializzato.
L'azienda ha effettuato diverse nomine chiave per espandere la sua piattaforma azionaria: Rob Muir come direttore generale e direttore associato della ricerca azionaria, un team proveniente da Autonomous Research che include John McDonald, Brian Foran e David Smith che si occupano dei settori bancari, Matt Coad focalizzato su FinTech, e i direttori generali Paul Durnan, David McCormick e Charles de Roziere che rafforzano le iniziative di vendita.
Truist Securities ha anunciado el nombramiento de Danielle Brill como directora general para fortalecer su cobertura de investigación de acciones en biotecnología. Brill, anteriormente en Raymond James, aporta experiencia en neurología, hematología y investigación de enfermedades autoinmunes. Se une al equipo existente de analistas de biotecnología y farmacéutica especializada.
La firma ha realizado varios nombramientos clave para expandir su plataforma de acciones: Rob Muir como director general y director asociado de investigación de acciones, un equipo de Autonomous Research que incluye a John McDonald, Brian Foran y David Smith que cubren los sectores bancarios, Matt Coad enfocado en FinTech, y los directores generales Paul Durnan, David McCormick y Charles de Roziere que refuerzan las iniciativas de ventas.
Truist Securities는 생명공학 주식 연구 범위를 강화하기 위해 Danielle Brill을 전무이사로 임명했다고 발표했습니다. Brill은 이전에 Raymond James에서 일했으며 신경학, 혈액학, 자가면역 질환 연구에 대한 전문성을 가지고 있습니다. 그녀는 기존의 생명공학 및 전문 제약 분석가 팀에 합류합니다.
회사는 주식 플랫폼을 확장하기 위해 여러 주요 임명을 했습니다: Rob Muir는 전무이사 및 주식 연구 부이사로, John McDonald, Brian Foran, David Smith가 포함된 Autonomous Research 팀은 은행 부문을 담당하고, Matt Coad는 FinTech에 집중하며, Paul Durnan, David McCormick, Charles de Roziere는 판매 이니셔티브를 강화합니다.
Truist Securities a annoncé la nomination de Danielle Brill en tant que directrice générale pour renforcer sa couverture de recherche sur les actions en biotechnologie. Brill, anciennement chez Raymond James, apporte son expertise en neurologie, hématologie et recherche sur les maladies auto-immunes. Elle rejoint l'équipe existante d'analystes en biotechnologie et en pharmacie spécialisée.
La société a effectué plusieurs nominations clés pour étendre sa plateforme d'actions : Rob Muir en tant que directeur général et directeur associé de la recherche sur les actions, une équipe d'Autonomous Research comprenant John McDonald, Brian Foran et David Smith couvrant les secteurs bancaires, Matt Coad se concentrant sur la FinTech, et les directeurs généraux Paul Durnan, David McCormick et Charles de Roziere renforçant les initiatives de vente.
Truist Securities hat die Ernennung von Danielle Brill zur Geschäftsführerin bekannt gegeben, um die Abdeckung seiner Aktienforschung im Bereich Biotechnologie zu stärken. Brill, zuvor bei Raymond James, bringt Expertise in der Neurologie, Hämatologie und Forschung zu Autoimmunerkrankungen mit. Sie tritt dem bestehenden Team von Analysten für Biotechnologie und Spezialpharmazeutika bei.
Das Unternehmen hat mehrere wichtige Ernennungen vorgenommen, um seine Aktienplattform zu erweitern: Rob Muir als Geschäftsführer und stellvertretender Direktor der Aktienforschung, ein Team von Autonomous Research, zu dem John McDonald, Brian Foran und David Smith gehören, das die Bankensektoren abdeckt, Matt Coad, der sich auf FinTech konzentriert, und die Geschäftsführer Paul Durnan, David McCormick und Charles de Roziere, die die Verkaufsinitiativen stärken.
- Strategic expansion of equity research coverage into high-growth sectors
- Significant strengthening of research team with experienced analysts
- Enhanced coverage of multiple financial sectors including banking, FinTech, and biotech
- None.
Danielle Brill joins firm's growing sales, trading, and research team
"Biotech continues to experience rapid evolution with new treatments and technologies, backed by compelling trial data, growing the market," said Mary Stroth, head of equity sales, trading, and research for Truist Securities. "Danielle's unique insights and analysis will complement our existing team as we advise our institutional clients to navigate factors that impact their investment strategies such as product innovation, loss of exclusivity, and new adjacency use cases."
Brill's coverage will complement the research from Truist Securities' existing biotech and specialty pharma analysts, including Asthika Goonewardene, Joon Lee, Srikripa Devarakonda, Nicole Germino, and Les Sulewski.
Prior to joining Truist Securities, Brill was a research analyst at Raymond James, where her coverage focused on neurology, hematology, and autoimmune diseases. She also served in research roles at Piper Sandler and Needham & Co. Brill's experience includes time as a clinical pharmacist at Mount Sinai and bench research at
"I am thrilled to join Truist Securities and collaborate with such a talented team," said Brill. "I look forward to bringing my experience in biotech research to help drive continued growth and success at the firm. This is a fantastic opportunity, and I can't wait to make a meaningful impact."
Brill is one of the latest additions to Truist Securities' growing equity sales, trading, and research team.
- Rob Muir joined the firm in early March as managing director and associate director of equity research, bringing more than two decades of experience across a variety of areas including corporate management, financial strategy, valuation, and investor engagement. Muir's background includes roles at Berenberg Bank, Morgan Stanley, and Price Waterhouse Cooper. He most recently served as chief financial officer of Creyon Bio.
- John McDonald, managing director, Brian Foran, managing director, and David Smith, vice president, joined the firm's equity research team late last year from Autonomous Research. The team recently initiated coverage of large cap banks, regional banks, consumer finance, and trust banks on the Truist Securities platform.
- Matt Coad, director, also joined the firm's equity research team late last year, focusing coverage on FinTech and payments sub-sectors. Coad's experience includes roles at Autonomous Research, Millennium, and Citi.
- Managing Directors Paul Durnan (
New York sales), David McCormick (New York sales trading), and Charles de Roziere (TMT sales) have strengthened the firm's sales initiatives. Durnan joined from RBC Capital Markets, McCormick from KeyBanc Capital Markets, and de Roziere from Citi.
"I'm proud of the exceptional talent we're building to strengthen our equity franchise," said Stroth. "Our focus is on strategic growth to best serve our clients by leveraging new technology and products along with high-touch service to deliver differentiated, data-driven content."
About Truist Securities
Truist Securities is the full-service corporate and investment banking arm of Truist Financial Corporation (NYSE: TFC). With a rich history extending back more than 125 years, Truist Securities offers a robust capital markets and investment banking platform that includes a comprehensive array of strategic advisory, mergers and acquisition, and capital markets capabilities for corporate and institutional clients, including sales, trading and research services in both fixed income and equity. The firm also provides corporate finance, asset finance, risk management, liquidity, and treasury management solutions to meet clients' full spectrum of financial needs. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/truist-securities-strengthens-its-biotech-equity-research-coverage-302410317.html
SOURCE Truist Financial Corporation
FAQ
What is the significance of Danielle Brill joining Truist Securities (TFC)?
How many new key appointments did Truist Securities (TFC) announce in their research team expansion?
What sectors will Truist Securities' (TFC) new research team cover?
What is Danielle Brill's background before joining Truist Securities (TFC)?
